Technology
Health
Pharmaceutical

Athenex

$14.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.16 (1.16%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Athenex and other stocks, options, ETFs, and crypto commission-free!

About

Athenex, Inc. Common Stock, also called Athenex, is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer.It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Read More The Oncology Innovation Platform segment involves in discovery and development of cancer supportive therapies. The Global Supply Chain Platform segment consists of manufacturing and marketing of API, medical devices, and clinical products. The Commercial Platform segment engages in manufacturing and selling of commercial pharmaceutical products. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Employees
582
Headquarters
Buffalo, New York
Founded
2003
Market Cap
927.91M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
349.67K
High Today
$14.07
Low Today
$13.60
Open Price
$13.82
Volume
140.59K
52 Week High
$20.90
52 Week Low
$9.38

Collections

Technology
Health
Pharmaceutical
Cancer Prevention
Biopharmaceutical
Medical
Manufacturing
Advertising and Marketing

News

Seeking AlphaMay 11

Athenex, Inc. CEO Johnson Lau on Q1 2019 Results - Earnings Call Transcript

Athenex, Inc. (NASDAQ:ATNX) Q1 2019 Earnings Conference Call May 9, 2019 8:00 AM ET Company Participants Tim McCarthy - Managing Director of LifeSci Advisors Johnson Lau - Chairman & CEO Randoll Sze - CFO Jeffrey Yordon - COO & President of Athenex Pharmaceutical Division Rudolf Kwan - Executive VP & Chief Medical Officer Conference Call Participants Kennen MacKay - RBC Capital Markets Chad Messer - Needham & Company Yale Jen - Laidlaw & Company Raymond Wu - Ladenburg Thalmann Peter Lawson - Sun...

276
Yahoo FinanceMay 9

Athenex: 1Q Earnings Snapshot

BUFFALO, N.Y. (AP) _ Athenex Inc. (ATNX) on Thursday reported a loss of $35.2 million in its first quarter. On a per-share basis, the Buffalo, New York-based company said it had a loss of 53 cents. The biopharmaceutical company posted revenue of $25.3 million in the period. Athenex shares have risen slightly more than 2% since the beginning of the year. The stock has declined 20% in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data fro...

230
NasdaqMay 9

Athenex, Inc. Announces First Quarter 2019 Financial Results and Provides Corporate Update

Positive Phase 3 data for KX2-391 featured at 2019 AAD Annual Meeting Promising early and complete response data reported for Oraxol in cutaneous angiosarcoma Topline results from Oraxol Phase III clinical trial expected August 2019 Presenting four abstracts featuring Athenex product candidates at 2019 ASCO annual meeting Approximately 100% year-over-year increase in Q1 product sales Conference Call and Live Audio Webcast at 8:00 a.m. Eastern Time today BUFFALO, N.Y., May 09, 2019 (GLOBE NEWSWIR...

196

Earnings

-$0.62
-$0.43
-$0.23
-$0.04
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 13, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.